COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,635 Articles (22,913 medRxiv, 8,722 bioRxiv)

Most recent first Previous |  Page 682: Articles 6811-6820  | Next

The COVID-19 Pandemic as an Opportunity for Unravelling the Causative Association between Respiratory Viruses and Pneumococcus-Associated Disease in Young Children: A Prospective Cohort Study
Dagan, R., van der Beek, B. A., Ben-Shimol, S., Greenberg, D., Shemer Avni, Y., Weinberger, D. M., Danino, D.
10.1101/2022.09.06.22279606 — Posted: 2022-09-06
Climate change has affected the spillover risk of bat-borne pathogens
Van de Vuurst, P., Qiao, H., Soler-Tovar, D., Escobar, L. E.
10.1101/2022.09.06.506814 — Posted: 2022-09-06
Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine
Lu, C., Zhang, Y., Liu, X., Hou, F., Cai, R., Yu, Z., Liu, F., Yang, G., Ding, J., Xu, J., Hua, X., Pan, X., Liu, L., Lin, K., Wang, Z., Li, X., Lu, J., Zhang, Q., Li, Y., Hu, C., Fan, H., Liu, X., Wang, H., Jia, R., Xu, F., Wang, X., Huang, H., Zhao, R., Li, J., Cheng, H., Jia, W., Yang, X.
10.1101/2022.09.06.506714 — Posted: 2022-09-06
Immune dynamics at single cell protein level after delta/omicron infection in COVID-19 vaccinated convalescent individuals
Bajaj, R., Yang, Z., Hammer, V., Poeschel, S., Beiber, K., Salker, M. S., Casadei, N., Ossowski, S., Riess, O., Singh, Y.
10.1101/2022.09.05.506626 — Posted: 2022-09-06
Resistance of SARS-CoV-2 Omicron Subvariant BA.4.6 to Antibody Neutralization
Wang, Q., Li, Z., Ho, J., Guo, Y., Yeh, A. Y., Liu, M., Wang, M., Yu, J., Sheng, Z., Liu, L., Ho, D. D.
10.1101/2022.09.05.506628 — Posted: 2022-09-06
Omicron-induced interferon signalling prevents influenza A virus infection
Bojkova, D., Bechtel, M., Rothenburger, T., Kandler, J. D., Hayes, L., Olmer, R., Martin, U., Jonigk, D., Ciesek, S., Wass, M. N., Michaelis, M., Cinatl, J.
10.1101/2022.09.06.506799 — Posted: 2022-09-06
Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunity
Amano, T., Yu, H., Amano, M., Leyder, E., Badiola, M., Ray, P., Kim, J., Ko, A. C., Achour, A., Weng, N.-p., Kochba, E., Levin, Y., Ko, M. S. H.
10.1101/2022.09.05.506686 — Posted: 2022-09-06
A multi-population-based genomic analysis uncovers unique haplotype variants and crucial mutant genes in SARS-CoV-2
Sheikh, A., Huang, H., Parvin, S., Badruzzaman, M., Ahmed, T., Hossain, E., Baran, I. S., Saud, Z. A.
10.1101/2022.09.05.22279597 — Posted: 2022-09-06
Scaling rules for pandemics: Estimating infected fraction from identified cases for the SARS-CoV-2 Pandemic
Ma, M., Zsolway, M., Tarafder, A., Bhanot, G.
10.1101/2022.09.05.22279599 — Posted: 2022-09-06
Community engagement to increase vaccine uptake: Quasi-experimental evidence from Islamabad and Rawalpindi, Pakistan
Abdullah, M., Ahmad, T., Kazmi, T., Sultan, F., Afzal, S., Safdar, R. M., Khan, A. A.
10.1101/2022.09.04.22279583 — Posted: 2022-09-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).